Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Myasthenia Gravis × remibrutinib × 30 days × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

rozanolixizumab 5 zilucoplan 3 ravulizumab 3 telitacicept 2 inebilizumab 2 fludarabine 2 Prednisone 2 Cyclophosphamide 2 thymoglobulin 1 remibrutinib 1 prednylidene 1 iptacopan 1 efgartigimod alfa 1 deltacortene 1 carmustine, poliferprosan 20 drug combination 1 Prednisolone 1 Peripheral Blood Stem Cell Transplantation 1 Melphalan 1 Etoposide 1 Cytarabine 1 Cladribine 1 Carmustine 1 Antilymphocyte Serum 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06744920 2026-02-20

RELIEVE

Novartis

Phase 3 Recruiting

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡